Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
The Lancet Infectious Diseases (2022) - Comments
pubmed: 34826381  doi: 10.1016/s1473-3099(21)00677-0  issn: 1473-3099  issn: 1474-4457 

Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri, Gustavo Jose Aroca Martinez, Marc Bonten, Reynaldo Chandler, Gonzalo Corral, Eddie Jan Louis De Block, Lucie Ecker, Julian Justin Gabor, Carlos Alberto Garcia Lopez, Lucy Gonzales, María Angélica Granados González, Nestor Gorini, Martin P Grobusch, Adrian D Hrabar, Helga Junker, Alan Kimura, Claudio F Lanata, Clara Lehmann